Access to medicines in the context of the right-to-health framework 2013, para. 24
Paragraph
Paragraph text
The Special Rapporteur was informed that pharmaceutical companies adopt various methods to reduce price transparency in order to work around any loss incurred from ERP. They introduce their products in high-price markets first, to be used as reference countries, thus maximizing the price. Additionally, transparency is reduced when companies list high prices in a country while granting discounts and rebates on the condition of confidentiality.
Legal status
Non-negotiated soft law
Body
Special Rapporteur on the right of everyone to the enjoyment of the highest attainable standard of physical and mental health
Document type
Special Procedures' report
Means of adoption
N.A.
Topic(s)
Economic Rights
Governance & Rule of Law
Health
Person(s) affected
N.A.
Year
2013
Paragraph type
Other
Reference
SR Health, Report to the HRC (2013), A/HRC/23/42, para. 24.